RUNX2 and plasma cell myeloma: Other groups have identified miRNAs in myeloma–EVs with a putative role in bone disease, such as miR-103a-3p, which once transferred to MSCs targeted Runx2 and led to decreased OB formation [172]; or miR-129-5p, which among other transcripts downregulated Sp-1, a transcription factor implicated in osteogenesis, and ALP, a known marker of early osteogenic differentiation [57].